High Tech Pharm Co., Ltd.

KOSDAQ:A106190 Stock Report

Market Cap: ₩157.7b

High Tech Pharm Past Earnings Performance

Past criteria checks 5/6

High Tech Pharm has been growing earnings at an average annual rate of 73.1%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 5.4% per year. High Tech Pharm's return on equity is 12.5%, and it has net margins of 17.9%.

Key information

73.1%

Earnings growth rate

76.7%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate5.4%
Return on equity12.5%
Net Margin17.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

A Look At The Intrinsic Value Of High Tech Pharm Co., Ltd. (KOSDAQ:106190)

Oct 23
A Look At The Intrinsic Value Of High Tech Pharm Co., Ltd. (KOSDAQ:106190)

Is High Tech Pharm (KOSDAQ:106190) Using Too Much Debt?

Aug 06
Is High Tech Pharm (KOSDAQ:106190) Using Too Much Debt?

Subdued Growth No Barrier To High Tech Pharm Co., Ltd. (KOSDAQ:106190) With Shares Advancing 25%

Jul 02
Subdued Growth No Barrier To High Tech Pharm Co., Ltd. (KOSDAQ:106190) With Shares Advancing 25%

There's Reason For Concern Over High Tech Pharm Co., Ltd.'s (KOSDAQ:106190) Massive 25% Price Jump

May 09
There's Reason For Concern Over High Tech Pharm Co., Ltd.'s (KOSDAQ:106190) Massive 25% Price Jump

Is High Tech Pharm (KOSDAQ:106190) A Risky Investment?

Apr 23
Is High Tech Pharm (KOSDAQ:106190) A Risky Investment?

We Think High Tech Pharm (KOSDAQ:106190) Has A Fair Chunk Of Debt

Feb 23
We Think High Tech Pharm (KOSDAQ:106190) Has A Fair Chunk Of Debt

Did High Tech Pharm's (KOSDAQ:106190) Share Price Deserve to Gain 91%?

Jan 19
Did High Tech Pharm's (KOSDAQ:106190) Share Price Deserve to Gain 91%?

What Is The Ownership Structure Like For High Tech Pharm Co., Ltd. (KOSDAQ:106190)?

Dec 15
What Is The Ownership Structure Like For High Tech Pharm Co., Ltd. (KOSDAQ:106190)?

Revenue & Expenses Breakdown

How High Tech Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A106190 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2481,55814,5583,2810
30 Jun 2483,50213,5223,1200
31 Mar 2482,54511,5962,7140
31 Dec 2376,7728,0762,6010
30 Sep 2379,1758,1141,9930
30 Jun 2394,1027,9312,3150
31 Mar 23102,1506,7992,5680
31 Dec 22102,9475,8732,7050
30 Sep 2288,68853,3370
30 Jun 2270,212-1,2053,1090
31 Mar 2267,869-2,9773,3170
31 Dec 2173,287-1,2253,3100
30 Sep 2179,120-1,0544,5150
30 Jun 2185,343-3674,9770
31 Mar 2179,496-2,5354,7270
31 Dec 2074,462-3,1524,5510
30 Sep 2072,142-5,6303,1820
30 Jun 2073,147-7,3402,6470
31 Mar 2067,977-4,7432,3970
31 Dec 1963,068-4,2182,3300
30 Sep 1961,495-9172,5950
30 Jun 1954,3811,1162,5690
31 Mar 1960,0132,4132,592-45
31 Dec 1866,3882,6082,5370
30 Sep 1869,8532,7112,1430
30 Jun 1870,4302,8631,972-16
31 Mar 1867,5932,6401,9281
31 Dec 1766,0502,1002,029101
30 Sep 1765,5344,8662,261120
30 Jun 1758,8473,5142,303136
31 Mar 1754,0814,4492,103164
31 Dec 1654,8365,2801,99119
30 Sep 1650,6603,0241,81560
30 Jun 1653,3735,4001,66455
31 Mar 1653,4526,2631,72466
31 Dec 1548,0926,5441,66480
30 Sep 1547,6048,6131,80745
30 Jun 1545,8449,0791,94650
31 Mar 1549,2647,0382,29940
31 Dec 1456,8977,8352,61825
30 Sep 1458,7406,6513,0840
30 Jun 1464,7225,5973,2470
31 Mar 1468,2489,2603,2000

Quality Earnings: A106190 has high quality earnings.

Growing Profit Margin: A106190's current net profit margins (17.9%) are higher than last year (10.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A106190 has become profitable over the past 5 years, growing earnings by 73.1% per year.

Accelerating Growth: A106190's earnings growth over the past year (79.4%) exceeds its 5-year average (73.1% per year).

Earnings vs Industry: A106190 earnings growth over the past year (79.4%) exceeded the Pharmaceuticals industry 23.8%.


Return on Equity

High ROE: A106190's Return on Equity (12.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/23 06:38
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

High Tech Pharm Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.